Iter-4360dd15-0066-transcript
第 66 轮执行轨迹
→ call search_memory({"limit":8,"query":"4360dd15 Tier A PMID aging trial abstract primary endpoint"}) → call list_recent({"n":8})
→ call list_by_tag({"limit":10,"tag":"4360dd15"})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0003-transcript", "tags": "iteration transcript", "modified": "20260424173843000", "preview": "!! 第 3 轮执行轨迹
→ call search_memory({\\\"limit\\\":10,\\\"query\\\":\\\"4360dd15 rapamycin senolytics NEXT_F"}, {"title": "Iter-4360dd15-0002-transcript", "tags": "iteration transcript", "modified": "20260424173549000", "preview": "!! 第 2 轮执行轨迹 → ca"}, {"title": "Iter-4360dd15-0009-transcript", "tags": "iteration transcript", "modified": "20260424175555000", "preview": "!! 第 9 轮执行轨迹 【tool:list_recent】
{"ok": true, "items": [{"title": "Iter-4360dd15-0065-reflection", "modified": "20260424200801000", "tags": "iteration reflection"}, {"title": "NEXT_FOCUS", "modified": "20260424200801000", "tags": "pinned focus"}, {"title": "先用题名锁定，再用终点分层", "modified": "20260424200801000", "tags": "lesson pubmed-verification stratification aging-evidence"}, {"title": "Iter-4360dd15-0065-transcript", "modified": "20260424200755000", "tags": "iteration transcript"}, {"title": "Iter-4360dd15-0065-minimal-relevance-decision-rules-for-retained-mtor-trials", "modified": "20260424200748000", "tags": "4360dd15 knowledge fact method stratification"}, {"title": "Iter-4360dd15-0064-reflection", "modified": "20260424200615000", "tags": "iteration reflection"}, {"title": "先用题名证据锁定研究性质", "modified": "20260424200615000", "tags": "lesson pubmed-verification audit clinical-trials"}, {"title": "Iter-4360dd15-0064-transcript", "modified": "20260424200608000", "tags": "iteration transcript"}]}
【tool:list_by_tag】
{"ok": true, "items": [{"title": "Iter-4360dd15-0065-minimal-relevance-decision-rules-for-retained-mtor-trials", "modified": "20260424200748000"}, {"title": "Iter-4360dd15-0064-relevance-tiering-10-pmids", "modified": "20260424200602000"}, {"title": "Iter-4360dd15-0063-10-pmid-audit-table", "modified": "20260424200432000"}, {"title": "Iter-4360dd15-0062-pubmed-title-verification-10-pmids", "modified": "20260424200328000"}, {"title": "Iter-4360dd15-0061-candidate-audit-10-remaining-pmids", "modified": "20260424200221000"}, {"title": "PMID 38310895 is a review, not a primary trial", "modified": "20260424200109000"}, {"title": "PMID 35040506 longitudinal analysis is embedded in primary trial", "modified": "20260424195939000"}, {"title": "Iter-4360dd15-0058-longevity-evidence-proximity-tagging", "modified": "20260424195827000"}, {"title": "Iter-4360dd15-0057-study-design-taxonomy-for-retained-trials", "modified": "20260424195711000"}, {"title": "Iter-4360dd15-0056-pubmed-boundary-confirmation", "modified": "20260424195548000"}]}
→ call read_note({"title":"NEXT_FOCUS"})
→ call read_note({"title":"Iter-4360dd15-0064-relevance-tiering-10-pmids"})
→ call read_note({"title":"Iter-4360dd15-0065-minimal-relevance-decision-rules-for-retained-mtor-trials"})
【tool:read_note】
{"ok": true, "title": "NEXT_FOCUS", "tags": "pinned focus", "text": "!! 下轮焦点（来自 mission 4360dd15 · Iter-0065）\n\n只攻克 Tier A 两篇最相关试验的摘要与主要终点，提炼出可直接复用的衰老相关判据。"}
【tool:read_note】
{"ok": true, "title": "Iter-4360dd15-0064-relevance-tiering-10-pmids", "tags": "4360dd15 knowledge fact critical-review stratification", "text": "!! 第 64 轮：10 条已保留 PMID 的最小相关性分层\n\n本轮不再争论它们是否为原始临床研究，而是按与衰老/长寿主问题的相关性强弱做最小分层。\n\n!! 分层结果\n\n!!! Tier A：直接指向衰老/老年功能表型\n判据：题名直接出现 ''older adults'' / ''biological ageing'' / 年龄相关功能终点（免疫、体能、认知）。\n- PMID 33977284 — ''Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials.''\n- PMID 29408453 — ''A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects.''\n\n!!! Tier B：年龄相关退行性病变，存在衰老邻近信号\n判据：对象本身是典型 age-related degeneration / neurodegeneration / 退行性表型，但题名未直接以衰老为干预目标。\n- PMID 35040506 — ''mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis.''\n- PMID 25525171 — ''Intravitreal sirolimus for the treatment of geographic atrophy: results of a phase I/II clinical trial.''\n\n!!! Tier C：原始临床试验，但与长寿主问题仅间接相关\n判据：主要适应症是安全性、剂量学或非衰老疾病；若要纳入长寿证据链，必须额外证明其反映了可泛化的 aging biology，而不能只靠 mTOR 药物身份。\n- PMID 22367193 — temsirolimus 心电安全性\n- PMID 18037627 — rheumatoid arthritis proof-of-concept\n- PMID 27613521 — tuberous sclerosis 癫痫\n- PMID 29992557 — metastatic breast cancer\n- PMID 24618547 — severe pulmonary hypertension\n- PMID 22115710 — diabetic macu
【tool:read_note】
{"ok": true, "title": "Iter-4360dd15-0065-minimal-relevance-decision-rules-for-retained-mtor-trials", "tags": "4360dd15 knowledge fact method stratification", "text": "!! 第 65 轮：10 条保留 PMID 的最小相关性判别规则\n\n本轮把上一轮的三层分级压缩成一个更可执行的三步判据，目标是避免以后再凭“mTOR 药物身份”误判为长寿证据。\n\n!! 规则 1：只要题名或摘要直接把“衰老/老年人/aging biology”设为研究目标，就归为 Tier A\n可验证信号：\n- ''older adults''\n- ''biology of ageing/aging''\n- 以免疫功能、体能、认知、frailty、inflammaging 作为主要终点或核心表型\n\n例子：\n- PMID 33977284 — ''Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials.''\n- PMID 29408453 — ''A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects.''\n\n证据来源：PubMed 题名；Europe PMC / 期刊页摘要可见免疫衰老与 older adults 直接挂钩。\n\n!! 规则 2：若对象是典型年龄相关退行性疾病，且摘要/题名出现 longitudinal biomarker / disease progression，可归为 Tier B\n可验证信号：\n- neurodegenerative / age-related degeneration / atrophy / progression\n- biomarker longitudinal analysis\n- 终点仍是疾病，但存在可解释的衰老邻近信号\n\n例子：\n- PMID 35040506 — 多系统萎缩（fatal neurodegenerative disease），并且有 ''1-Year Biomarker Longitudinal Analysis''；web 检索摘要指出 blood NfL 和 whole brain volume 的变化与 UMSARS progression 相关。\n- PMID 25525171 — geographic atrophy（年龄相关黄斑变性邻近表型）\n\n判定边界：Tier B 不能自动升级为长寿证据；只有当 biomarker 或功能终点能明确对应 aging biology 时，才可向 Tier A 靠拢。\n\n!! 规则 3：若主要是别的疾病、安全性、剂量学或概念验证，而没有年龄相关终点，则维持 Tier C\n可验证信号：\n- disease-specific safety / feasi
→ call web_fetch({"max_chars":7000,"url":"https://pubmed.ncbi.nlm.nih.gov/33977284/"})
→ call web_fetch({"max_chars":7000,"url":"https://pubmed.ncbi.nlm.nih.gov/29408453/"})
【tool:web_fetch】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://pubmed.ncbi.nlm.nih.gov/33977284/'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
【tool:web_fetch】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://pubmed.ncbi.nlm.nih.gov/29408453/'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
→ call web_search({"limit":5,"query":"33977284 abstract primary endpoint older adults mTOR inhibitors immune function PubMed"})
→ call web_search({"limit":5,"query":"29408453 abstract primary endpoint rapamycin older human cohort immunological physical performance cognitive effects PubMed"})
【tool:web_search】
{"ok": true, "query": "33977284 abstract primary endpoint older adults mTOR inhibitors immune function PubMed", "results": [{"title": "Targeting the biology of ageing with mTOR inhibitors to improve immune ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8102040/", "snippet": "Abstract Background The COVID-19 pandemic highlights the need for therapies that improve immune function in older adults , including interferon (IFN)-induced antiviral immunity that declines with age. In a previous phase 2a trial, RTB101 (previously known as BEZ235), an oral mechanistic target of rapamycin ( mTOR ) inhibitor , was observed to increase IFN-induced antiviral gene expression and ..."}, {"title": "Targeting the biology of ageing with mTOR inhibitors to improve immune ...", "url": "https://europepmc.org/article/MED/33977284", "snippet": "The COVID-19 pandemic highlights the need for therapies that improve immune function in older adults , including interferon (IFN)-induced antiviral immunity that declines with age. In a previous phase 2a trial, RTB101 (previously known as BEZ235), an oral mechanistic target of rapamycin ( mTOR ..."}, {"title": "Targeting the biology of ageing with mTOR inhibitors to improve immune ...", "url": "https://www.unboundmedicine.com/medline/citation/33977284/Targeting_the_biology_of_ageing_with_mTOR_inhibitors_to_improve_immune_function_in_older_adults:_phase_2b_and_phase_3_randomised_trials_", "snippet": "The COVID-19 pandemic highlights the need for therapi
【tool:web_search】
{"ok": true, "query": "29408453 abstract primary endpoint rapamycin older human cohort immunological physical performance cognitive effects PubMed", "results": [{"title": "PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/", "snippet": "PubMed ® comprises more than 40 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full text content from PubMed Central and publisher web sites."}, {"title": "A randomized control trial to establish the feasibility and safety of ...", "url": "https://database.clin-star.org/display/pmid-29408453", "snippet": "Erythrocyte Indices Female Glucose Tolerance Test Hand Strength Humans Immunosuppressive Agents Insulin Resistance Male Myeloid Cells Physical Fitness Pilot Projects Prospective Studies Sirolimus T-Lymphocytes, Regulatory TOR Serine-Threonine Kinases Texas Walk Test Blood cell subsets Cytokines Geriatrics Physiological outcomes Rapamycin mTOR ..."}, {"title": "A randomized control trial to establish the feasibility and safety of ...", "url": "https://www.sigmaaldrich.com/US/en/tech-docs/paper/1464150", "snippet": "A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort : Immunological , physical performance , and cognitive effects ."}, {"title": "A randomized control trial to establish the feasibility and safety of ...", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0531556517309130", "s
→ call web_search({"limit":8,"query":"Europe PMC 29408453 abstract rapamycin older human cohort physical performance cognitive effects"})
→ call web_search({"limit":8,"query":"29408453 primary endpoint abstract physical performance cognitive effects older human cohort"})
【tool:web_search】
{"ok": true, "query": "Europe PMC 29408453 abstract rapamycin older human cohort physical performance cognitive effects", "results": [{"title": "A randomized control trial to establish the feasibility ... - Europe PMC", "url": "https://europepmc.org/article/MED/29408453", "snippet": "A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort : Immunological, physical performance , and cognitive effects ."}, {"title": "A randomized control trial to establish the feasibility and safety of ...", "url": "https://database.clin-star.org/display/pmid-29408453", "snippet": "Erythrocyte Indices Female Glucose Tolerance Test Hand Strength Humans Immunosuppressive Agents Insulin Resistance Male Myeloid Cells Physical Fitness Pilot Projects Prospective Studies Sirolimus T-Lymphocytes, Regulatory TOR Serine-Threonine Kinases Texas Walk Test Blood cell subsets Cytokines Geriatrics Physiological outcomes Rapamycin mTOR ..."}, {"title": "PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/", "snippet": "PubMed® comprises more than 40 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full text content from PubMed Central and publisher web sites."}, {"title": "A randomized control trial to establish the feasibility and safety of ...", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0531556517309130", "snippet": "A randomized control trial to establ
【tool:web_search】
{"ok": true, "query": "29408453 primary endpoint abstract physical performance cognitive effects older human cohort", "results": [{"title": "A randomized control trial to establish the feasibility and safety of ...", "url": "https://www.sigmaaldrich.com/US/en/tech-docs/paper/1464150", "snippet": "A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort : Immunological, physical performance , and cognitive effects ."}, {"title": "Association Between Physical Performance and Cognitive Function in ...", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679973/", "snippet": "The relationship between Digit Symbol Substitution Task and physical function performance demonstrated a stronger magnitude of association compared to the Mini-Mental Status Examination or Montreal Cognitive Assessment."}, {"title": "The benefits of physical exercise on older adults' cognitive function ...", "url": "https://www.sciencedirect.com/science/article/pii/S1469029224000967", "snippet": "This study explores the concurrent and delayed (two years later) associations between physical exercise and older adults' cognitive function. This study also investigates the mediating roles of three negative physical , psychological, and social resources: limitations in daily abilities, depressive mood, and isolation from friends, as well as the moderating roles of cognitive reserve on these"}, {"title": "Observational evidence of the associatio
→ call web_fetch({"max_chars":9000,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8102040/"})
→ call web_fetch({"max_chars":9000,"url":"https://europepmc.org/article/MED/29408453"})
【tool:web_fetch】
{"ok": true, "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8102040/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials - PMC Skip to main content An official website of the United States government Here's how you know Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. Search Log in Dashboard Publications Account settings Log out Search… Search NCBI Primary site navigation Search Logged in as: Dashboard Publications Account settings Log in Search PMC Full-Text Archive Search in PMC Journal List User Guide PERMALINK Copy As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright Notice Lancet Healthy Longev . 2021 May 6;2(5):e250–e262. doi: 10.1016/S2666-7568(21)00062-3 Search in PMC Search in PubMed View in NLM Catalog Add to search Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials Joan B Man
【tool:web_fetch】
{"ok": true, "url": "https://europepmc.org/article/MED/29408453", "status": 200, "content_type": "text/html;charset=UTF-8", "text": "Europe PMC Europe PMC 1 Sign in | Create an account https://orcid.org https://plus.europepmc.org Europe PMC Menu About About Europe PMC Preprints in Europe PMC Funders Become a funder Governance Roadmap Outreach Tools Tools overview Article status monitor Grant finder External links service RSS feeds About SciLite annotations Annotations submission service Developers Developer resources Articles RESTful API Grants RESTful API API case studies SOAP web service Annotations API OAI service Bulk downloads Developers Forum Support User guide Search syntax guide Contact us Contact us Helpdesk Feedback Twitter Blog Tech blog Developer Forum Europe PMC plus NOTICE: The ORCID Claiming tool has been temporarily disabled, because of technical issues. Please check back in later.", "truncated": false}
→ call web_search({"limit":10,"query":"\"A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort\" abstract"})
→ call web_search({"limit":10,"query":"\"29408453\" rapamycin older human cohort abstract trial"})
【tool:web_search】
{"ok": true, "query": "\"A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort\" abstract", "results": [{"title": "A Randomized Control Trial to Establish the Feasibility and Safety of ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5869166/", "snippet": "A Randomized Control Trial to Establish the Feasibility and Safety of Rapamycin Treatment in an Older Human Cohort : Immunological, Physical Performance, and Cognitive Effects"}, {"title": "A randomized control trial to establish the feasibility and safety of ...", "url": "https://scholars.uthscsa.edu/en/publications/a-randomized-control-trial-to-establish-the-feasibility-and-safet/", "snippet": "Fingerprint Dive into the research topics of ' A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort : Immunological, physical performance, and cognitive effects'. Together they form a unique fingerprint."}, {"title": "A Randomized Control Trial To Establish The Feasibility and Safety of ...", "url": "https://www.scribd.com/document/891489723/A-Randomized-Control-Trial-to-Establish-the-Feasibility-and-Safety-of-Rapamycin-Treatment-in-an-Older-Human-Cohort-Immunological-Physical-Performanc", "snippet": "A Randomized Control Trial To Establish The Feasibility and Safety of Rapamycin Treatment in An Older Human Cohort - Immunological, Physical Performance, and Cognitive Effects - ScienceDirect This
【tool:web_search】
{"ok": true, "query": "\"29408453\" rapamycin older human cohort abstract trial", "results": [{"title": "PDF Progress Report Publication List Analytical Pharmacology and Drug ...", "url": "https://wp.uthscsa.edu/nathan-shock/wp-content/uploads/sites/176/2021/06/Pharmacology-Publication-List-101519.pdf", "snippet": "AD, Curiel TJ, Javors MA, Musi N, Chiodo L, Koek W, Gelfond JAL, Kellogg DL, Jr. A randomized control trial to establish the feasibility and safety of rapamycin treatment in n older human cohort : Immunol gical, physical performance, and cognitive effects Exp Gerontol. 2018;105:53-69. Epub 2018/ PubMed PMID: 29408453 ; PMCID: PMC5869166."}]}
→ call web_fetch({"max_chars":9000,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5869166/"})
【tool:web_fetch】
{"ok": true, "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5869166/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "A Randomized Control Trial to Establish the Feasibility and Safety of Rapamycin Treatment in an Older Human Cohort: Immunological, Physical Performance, and Cognitive Effects - PMC Skip to main content An official website of the United States government Here's how you know Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. Search Log in Dashboard Publications Account settings Log out Search… Search NCBI Primary site navigation Search Logged in as: Dashboard Publications Account settings Log in Search PMC Full-Text Archive Search in PMC Journal List User Guide PERMALINK Copy As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright Notice Exp Gerontol . Author manuscript; available in PMC: 2019 May 1. Published in final edited form as: Exp Gerontol. 2018 Feb 3;105:53–69. doi: 10.1016/j.exger.2017.12.026 Search in PMC Search in PubMed View in NLM Catalog Add to search A Randomized Control Tria
→ call write_note({"tags":["4360dd15","knowledge","fact","method","stratification"],"text":"!! 第 66 轮：Tier A 两篇试验的摘要与主要终点抽取\n\n本轮只攻克 Tier A 的两篇最相关试验，目标是把“衰老相关判据”压缩成可复用的、可直接审稿的抽取规则。\n\n!! PMID 33977284\n'''题名'''：Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials.\n\n'''摘要里可直接复用的衰老相关信号'''\n- 研究对象：''adults aged at least 65 years''，明确是)
【tool:write_note】
{"ok": true, "path": "C:\\Users\\yh599\\Documents\\GitHub\\LLM-yh\\Sisyphus\\wiki\\tiddlers\\Iter-4360dd15-0066-TierA-abstracts-and-endpoints-for-aging-criteria.tid", "title": "Iter-4360dd15-0066-TierA-abstracts-and-endpoints-for-aging-criteria"}
【assistant】
本轮已完成：只攻克 Tier A 的两篇最相关试验，并把它们的摘要与主要终点抽成可复用判据。
要点：
- PMID 33977284：明确是 older adults，研究目标直接是 improve immune function in older adults，主要终点是 RTI / symptomatic respiratory illness，因此可作为免疫衰老功能代理证据。
- PMID 29408453：明确是 older human cohort (70–95)，评估认知、体能、免疫老化多域表型，虽然主轴是 feasibility/safety，但已直接触及衰老相关终点，因此也应归 Tier A。
- 共同可复用规则：只要同时满足“older adults/older cohort” + “age/aging/immune aging” + “认知/体能/感染/frailty 等功能终点”中的任意两项，就不应再把它当作普通 mTOR 药物试验。
已沉淀到记忆：
- Iter-4360dd15-0066-TierA-abstracts-and-endpoints-for-aging-criteria
<NEXT_FOCUS>下一轮只做一件事：把这两篇 Tier A 试验的“主终点是否可外推到长寿证据链”做成严格判据，区分 surrogate aging endpoint 与真正 longevity endpoint。</NEXT_FOCUS>
```